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Patellamides are macrocyclic peptides with potent biological effects and are a
subset of the cyanobactins. Cyanobactins are natural products that are produced
by a series of enzymatic transformations and a common modification is the
addition of a prenyl group. Puzzlingly, the pathway for patellamides in
Prochloron didemni contains a gene, patF, with homology to prenylases, but
patellamides are not themselves prenylated. The structure of the protein PatF
was cloned, expressed, purified and determined. Prenylase activity could not
be demonstrated for the protein, and examination of the structure revealed
changes in side-chain identity at the active site. It is suggested that these changes
have inactivated the protein. Attempts to mutate these residues led to unfolded
protein.
1. Introduction
Medicinal chemists have for many decades looked towards natural
products as a scaffold for the design of new drug molecules; however,
their synthesis can often be challenging. The exploration of natural
product biosynthetic pathways allows the potential exploitation of
these pathways to produce new chemical entities. In order to achieve
this, study of the individual enzymes involved can give great insight
into both their function and the potential to manipulate them for
novel purposes.
The cyanobactins, which are a natural product superfamily, are
cyclic peptides containing a range of post-translational modifications
including heterocyclization, epimerization and prenylation, and have
a wide range of biological activities (Sivonen et al., 2010). The most
widely studied members of the cyanobactins are the patellamides
produced by Prochloron didemni, an obligate symbiont of the sea
squirt Lissoclinum patella. The patellamides are eight-residue cyclic
peptides containing oxazolines, thiazoles and d-amino acids and are
derived from a ribosomally produced precursor peptide. This peptide
is chemically modified by a series of enzymes that includes proteases,
heterocyclases and macrocyclases (Fig. 1a; Houssen & Jaspars, 2010).
The patellamide gene cluster has been identified (seven genes; patA–
patG) and the majority of the proteins or their contributing domains
have been assigned specific functions (Schmidt et al., 2005). The
crystal structures of the protease domain of PatA and the macro-
cyclase domain of PatG have previously been reported and their
mechanisms have been elucidated (Koehnke et al., 2012; Houssen et
al., 2012; Agarwal et al., 2012).
PatF has been shown to be essential for patellamide production in
vivo; however, to date its function has not been confirmed (Donia et
al., 2006). Cyanobactin family members related to PatF have been
shown to possess prenyltransferase activity. LynF from Lyngbya
aestuarii prenylates tyrosine residues on the aestuaramide family of
cyanobactins via a Claisen rearrangement (Fig. 1b; McIntosh et al.,
2011; McIntosh et al., 2013), while TruF1 from Prochloron spp.
prenylates threonine and serine residues on the trunkamides (Fig. 1c;
Tianero et al., 2012). These enzymes have sequence homologies to
PatF of 44 and 41%, respectively.
Protein prenylation is a common post-translational modification
that plays a role in protein–protein interactions and membrane
tethering (Novelli & D’Apice, 2012). In cyanobactins, prenylation of
hydroxyl groups occurs via a 3-methyl-but-2-en-1-yl group derived
from dimethylallyl pyrophosphate (DMAPP) and is catalyzed by the
cyanobactin-specific family of prenyltransferases (McIntosh et al.,
2011).
To date, no prenylation of isolated natural patellamides is evident.
No tyrosine residues are found in natural patellamides and therefore
if PatF is mechanistically similar to LynF then there is no substrate to
prenylate. Secondly, threonines and serines are heterocyclized at an
early stage in the patellamide-biosynthetic pathway, eliminating them
as substrates. In the closely related trunkamide pathway these resi-
dues are not heterocyclized and are prenylated by TruF1.
Here, we report the crystal structure of PatF, the first from this
cyanobactin enzyme family, to a resolution of 2.1 A˚ and provide
evidence to suggest that it is likely to be an inactive prenyltransferase.
2. Methods
2.1. Expression and purification
The full-length patF gene from P. didemni was synthesized and
cloned in pJexpress 411 plasmid (DNA 2.0) with an N-terminal His6
tag and a Tobacco etch virus (TEV) protease site. The resulting
protein was expressed in Escherichia coli BL21 (DE3) cells grown on
auto-induction medium using the method of Studier (2005). Cultures
were grown for 48 h at 293 K.
l-Selenomethionine-labelled (SeMet) PatF was expressed inE. coli
BL21 (DE3) cells, cultures of which were grown in minimal medium
supplemented with glucose-free nutrient mix (Molecular Dimen-
sions) and 5% glycerol. The medium was inoculated with an over-
night culture grown in Luria–Bertani (LB) medium and washed three
times with minimal medium. After 15 min of growth at 310 K,
60 mg l1 l-selenomethionine was added to the cultures. An amino-
acid mix (100 mg l1 lysine, phenylalanine and threonine, 50 mg l1
isoleucine and valine) was added to the cultures when they reached
an OD600 nm of 0.6. After 15 min of further growth at 310 K the
cultures were induced with 1 mM isopropyl -d-1-thiogalacto-
pyranoside (IPTG) and grown for 30 h at 293 K.
For native and SeMet PatF, cells were harvested by centrifugation
(4000g, 277 K, 20 min) and resuspended in lysis buffer [150 mM
NaCl, 20 mM Tris–HCl pH 8.0, 20 mM imidazole pH 8.0, 0.1%(v/v)
Triton X-100, 3 mM -mercaptoethanol (BME)] with the addition of
Complete EDTA-free protease-inhibitor tablets (Roche) and 0.4 mg
DNAse I (Sigma) per gram of wet cells. They were then lysed by
passage through a cell disrupter at 207 MPa (Constant Systems). The
lysate was cleared by centrifugation (40 000g, 277 K, 20 min) and
loaded onto an Ni-Sepharose 6 FF column (GE Healthcare) equili-
brated in lysis buffer. The column was washed with lysis buffer and
PatF was eluted with 250 mM imidazole in the same buffer. The
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Figure 1
Structures of cyanobactins: (a) patellamide A, (b) an aestuaramide and (c)
trunkamide A. Prenyl groups are coloured red.
Table 1
Data-collection and refinement statistics for SeMet PatF (PDB entry 4bg2).
Values in parentheses are for the highest resolution shell (where applicable).
Data collection
Beamline I04, DLS
Wavelength (A˚) 0.979
Space group P21
Unit-cell parameters (A˚, ) a = 47.08, b = 135.80, c = 48.74,
 =  = 90.0,  = 118.5
Resolution range (A˚) 35.32–2.13 (2.19–2.13)
Total No. of reflections 280235
No. of unique reflections 29355
Multiplicity 9.5 (9.8)
Completeness (%) 97.9 (97.5)
Mean I/(I) 14.0 (3.5)
Rmerge 0.10 (0.69)
Anomalous completeness (%) 97.9 (97.6)
Anomalous multiplicity 4.8 (4.9)
Refinement
Rwork/Rfree (%) 19.0/22.1
R.m.s.d., bond lengths (A˚) 0.009
R.m.s.d., angles () 1.314
No. of atoms
Protein 4865
Water 86
B factors (A˚2)
Protein 41.6
Water 40.0
elution peak was passed over a desalting column pre-equilibrated in
150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP, 10% glycerol.
TEV protease was added at a mass ratio of 1:5 and the protein was
digested for 2 h at 293 K to remove the His6 tag. The cleaved protein
was loaded onto a second nickel column and PatF was found in the
flowthrough. The protein was concentrated (Vivaspin concentrators,
10K molecular-weight cutoff) and applied onto a Superdex 75 gel-
filtration column (GE Healthcare) equilibrated in the desalting
column buffer. The protein eluted as a monomer and was confirmed
by SDS–PAGE and mass spectrometry (MS). SeMet PatF was addi-
tionally confirmed to contain the expected three selenomethionine
residues by mass spectrometry. The protein was of full length with the
exception of the N-terminal methionine, which was removed during
TEV protease cleavage, and the addition of an Arg and a Ser residue
at the C-terminus, which were artifacts from cloning.
2.2. Crystallization, structure solution and refinement
Crystals of SeMet PatF were grown in a condition consisting of
0.1M sodium/potassium tartrate, 26% PEG 2K MME at 293 K using
the hanging-drop vapour-diffusion method. The quality of the crystals
was found to be improved following iterative rounds of seeding.
Crystals of native PatF were grown under the same conditions, but
were of poorer diffraction quality.
A single crystal was cryoprotected in a solution of mother liquor
supplemented with 30% glycerol and was flash-cooled in a stream of
nitrogen at 100 K. A single-wavelength anomalous dispersion (SAD)
data set was collected at the Se K absorption edge (0.979 A˚ wave-
length) at 100 K on beamline I04 at DLS. The data were processed
and scaled in xia2 (Winter, 2010) using XDS (Kabsch, 2010) and
SCALA (Evans, 2006) to a resolution of 2.13 A˚. The structure was
solved using AutoSol in PHENIX and automated model building of
the chains was carried out usingAutoBuild in PHENIX (Adams et al.,
2010). The model was refined by iterative cycles of manual rebuilding
using Coot (Emsley et al., 2010) and refinement using REFMAC5
(Murshudov et al., 2011) in the CCP4 suite (Winn et al., 2011). TLS
restraints were calculated using the TLSMD server (Painter &
Merritt, 2006) and were used in refinement (Winn et al., 2001). PISA
was used to assess the oligomeric state of the protein (Krissinel &
Henrick, 2007). The structure was validated using MolProbity (Chen
et al., 2010) and the coordinates were deposited in the Protein Data
Bank (PDB entry 4bg2).
Homology models of LynFand TruF1 were created using the ‘one 2
one threading’ module of Phyre2 (Kelley & Sternberg, 2009) by
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Figure 2
X-ray crystal structure of PatF. (a) ‘Chainbows’ representation of the asymmetric unit showing the presence of two molecules. (b) Secondary-structure representation of the
PatF monomer; -helices are shown in red and -sheets are shown in yellow. PatF is formed by a 12-stranded antiparallel -barrel surrounded on the outside by 12 -helices,
with -helix 1 protruding out from the rest of the structure.
Figure 3
Electrostatic surface-potential map of PatF rotated around 180. The central pore of the -barrel, which is the presumed binding site, is highly electronegative (red), with
only minor electropositive patches (blue) found at the pore entry.
inputting the sequence of interest and the SeMet PatF structural
coordinates.
Structure alignments were carried out using the SSM Superpose
feature of Coot and all structures were presented using PyMOL
(DeLano, 2002), with the exception of the electrostatic potential
maps, which were presented using CCP4mg (McNicholas et al., 2011).
Sequence alignments were carried out using ClustalW (Larkin et
al., 2007) and were presented using ALINE (Bond & Schu¨ttelkopf,
2009).
2.3. Biological assays
Assays were set up to assess potential prenylation by PatF under
conditions adapted from McIntosh et al. (2011). PatF at a concen-
tration of 4–10 mM was incubated with 0.1–1 mM Boc amino-acid
derivative (Boc-Ser, Boc-Tyr or Boc-Trp), 10 mM HEPES pH 7.5,
10–100 mMMgCl2, 3 mM tris(2-carboxyethyl)phosphine (TCEP) and
0.5–1 mM DMAPP. All reactions were incubated at 310 K for either
24 h or 7 d. Reactions were analysed by MS.
3. Results
3.1. Overall protein structure
The protein crystals belonged to space group P21, with two
biological monomers in the asymmetric unit (Fig. 2a). Four Se sites,
corresponding to two selenomethionines per monomer, were identi-
fied. The third selenomethionine residue in each monomer is posi-
tioned in a disordered loop.
PatF is formed by a 12-stranded antiparallel -barrel surrounded
on the outside by 12 -helices in a similar manner to the TIM-barrel
motif (Banner et al., 1976; Fig. 2b); -helix 1 protrudes out from the
remainder of the structure. There is a single disulfide bridge at the
C-terminus linking Cys276 and Cys307. The final refined model
contains residues 3–196 and 205–307 of chain A and residues 2–196
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Figure 4
Electrostatic surface-potential maps of two PatF homologues. The structures of these proteins were generated using ‘one 2 one threading’ in Phyre2. Maps are rotated 180 to
view both sides of the pore. (a) LynF, (b) TruF1. In contrast to PatF, both enzymes have electropositive patches in the central pore of the -barrel.
Figure 5
Structural alignment of PatF (green) and DMATS (cyan) highlighting the key
residues involved in DMATS–DMAPP binding and their absence in PatF. Lys187 of
DMATS forms a salt bridge to the phosphate O atom of the DMAPP mimic
(2.67 A˚), while Asp178 forms a stabilizing interaction with Arg100, which in turn
forms a salt bridge to the DMAPP mimic. In PatF, Lys187 and Asp178 correspond
to Met136 and His125, respectively. These residue changes would abolish these
DMAPP-binding interactions.
and 205–307 of chain B. The missing residues are found on the
connecting loop between 8 and 8 and also at the N- and C-termini,
all of which are presumed to be disordered. PatF is a globular protein
with approximate dimensions of 45  43 53 A˚. Analysis with PISA
suggests that PatF exists as a monomer in solution, consistent with gel
filtration. Full data-collection and refinement statistics can be found
in Table 1.
Electrostatic surface-potential representations of PatF highlight a
highly electronegative central pore that could disfavour binding of
the electronegative DMAPP (Fig. 3). Attempts to solve a crystal
structure of a complex with DMAPP were unsuccessful, with no
electron density for the ligand present in any of the structures.
3.2. Biological assays
Prenylation assays were set up using PatF with the Boc amino-acid
derivatives Boc-Ser, Boc-Tyr and Boc-Trp. In all reactions only the
original starting masses of both the Boc amino acid and the DMAPP
molecule were observed by MS, confirming a lack of prenylation.
3.3. Homology-model building
To further clarify potential DMAPP binding, we sought to generate
homology models of related cyanobactin family members which have
been confirmed to function as prenyltransferases. LynF and TruF1
homology models have electrostatic surface potential maps with clear
electropositive regions. Neither has the same highly electronegative
character as PatF (Fig. 4).
3.4. Structure overlays and sequence alignments
To further characterize the potential binding site of PatF, we
performed structural alignments with dimethylallyl tryptophan
synthase (DMATS) from Aspergillus fumigatus (Metzger et al., 2009;
PDB entry 3i4x). DMATS is a known prenyltransferase and its
structure was solved in the presence of both the amino acid and a
DMAPP mimic. DMATS is considerably different from PatF in
sequence homology (<5%), yet both contain the same characteristic
-barrel pore surrounded by -helices. Focusing on the DMAPP-
binding site allowed us to assess which interactions may be involved
in DMAPP binding in PatF and indeed in related cyanobactin family
members (Fig. 5). Two key interactions of DMATS were identified
to involve Lys187 and Asp178, which both play a role in binding
DMAPP. Lys187 forms a strong salt bridge to the phosphate O atom
(2.6 A˚), while Asp178 forms a stabilizing interaction with Lys187 and
also with Arg100, which in turn forms a salt bridge to the DMAPP
molecule. In PatF, the structurally equivalent residues to Lys187 and
Asp178 are Met136 and His125, respectively. These significant
changes mean that Met136 would not form the same salt-bridge
interaction as the lysine in DMATS, while His125 would have a
repulsive effect on Arg66 (the equivalent of Arg100 in DMATS)
rather than a stabilizing interaction.
Upon examination of sequence alignments of the PatF family of
enzymes from cyanobactin pathways, Met136 and His125 of PatF are
found to correspond to Lys/Arg and Asp, respectively (i.e. they are
closely related to those in DMATS; Fig. 6; a full sequence alignment
is available in the Supplementary Material1). As LynF and TruF1 are
active using DMAPP as a substrate, we suggest that the amino-acid
substitutions in PatF lead to its inability to bind DMAPP and lack of
prenyltransferase activity. Gly127 in PatF corresponds to an arginine
residue in the other cyanobactin family members and the structurally
equivalent residue in DMATS is a lysine (Lys180). Lys180 in DMATS
and Gly127 in PatF are both sited at the pore opening in their
respective structures but do not appear to be directly involved in
binding. Attempts to mutate PatF in order to design in an active site
based on the other cyanobactin proteins resulted in insoluble protein
expression only. The single mutant M136K and the triple mutant
H125D/G127R/M136K were insoluble when expressed under the
same conditions as native PatF.
4. Discussion
The crystal structure of PatF has been solved and comprises a
-barrel core surrounded by -helices, which is a known motif for
prenyltransferases. We have created electrostatic potential maps,
performed structural alignments with a prenyltransferase in complex
with DMAPP, examined sequence alignments with related proteins
and assessed prenylation in biological assays. Our data, together with
the lack of prenylation of any natural patellamide, indicate that PatF
is an inactive prenyltransferase.
Donia et al. (2006) have reported that PatF is essential for patel-
lamide production in vivo and therefore it must be responsible for
another function. As the structure does not give any insight into what
role this may be, further study will be required.
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